# AnaptysBio Inc. (ANAB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $56.80, market value $1.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). AnaptysBio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.12**. A PEG of 0.12 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.2×**. Each dollar of revenue is priced at 7.2×.
- **Price / book: 129.4×**. The shares trade at 129.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 0.3%** (5-yr avg -20.8%). Free cash flow equals 0.3% of the market value, above its five-year average of -20.8%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: 17.6%**. 17.6% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -5.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -35.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -7.4%**. Each dollar of assets produces -7.4% of profit.

## Growth
- **Revenue growth (1 yr): 157.0%** (3-yr 183.6%/yr, 5-yr 25.6%/yr). Revenue grew 157.0% over the last year, against 25.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 91.0%**. Earnings per share rose 91.0%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 9.07** (quick 9.07). Current assets cover the next year's liabilities 9.07 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. AnaptysBio Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover AnaptysBio Inc.; the consensus is strong_buy, with an average price target of $86.64 (+53% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 304.0%** (YTD 75.7%, 3-mo 12.8%). The shares are up 304.0% over twelve months including dividends.
- **From 52-week high: -21.5%** (398.1% above the low). Trading 22% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 0.97** (volatility 72%). Beta of 0.97 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ANAB · Page: https://foliofundamentals.com/stocks/anab

Not investment advice.